AREC — Arecor Therapeutics Cashflow Statement
0.000.00%
- £36.75m
- £30.34m
- £4.57m
Annual cashflow statement for Arecor Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 7 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.57 | -3.51 | -6.95 | -10.5 | -8.9 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 0.286 | 0.445 | 0.985 | 0.346 | 0.388 |
Other Non-Cash Items | |||||
Changes in Working Capital | 0.928 | 1.04 | 0.339 | -0.925 | 2.18 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -0.268 | -1.86 | -5.45 | -10.8 | -5.84 |
Capital Expenditures | -0.019 | -0.052 | -0.069 | -0.345 | -0.151 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0.005 | 0.003 | 0.001 | -7.65 | 6.67 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.013 | -0.049 | -0.068 | -7.99 | 6.52 |
Financing Cash Flow Items | -0.008 | -0.083 | -1.46 | -0.38 | -0.015 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.076 | 1.77 | 20.9 | 5.16 | -0.18 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.373 | -0.175 | 15.4 | -13.6 | 0.328 |